Hypolipidemic Agents (Antihyperlipidemics)

11/09/1988 - "[New guidelines for the management of hyperlipidemia: change of diet is more effective than antilipemic agents]."
07/01/1996 - "Recently, short-term studies have shown that newer antilipemic agents appear to be safe and effective in treating hyperlipidemia in this population. "
03/01/2015 - "Our results demonstrate that the zebrafish hyperlipidemia model developed and validated in this study could be used for in vivo hyperlipidemia studies and drug screening and for assessing hypolipidemic drugs with different mechanisms."
08/01/2010 - "This finding may indicate that early initiation of antihyperlipidemics in patients with familial hyperlipidemias may decrease the risk of future atherosclerotic events through not only decreasing the serum lipid levels, but also decreasing plasma vWf:Ag levels."
01/01/2009 - "Clinical problem are therapy dilemas about the women who were treated with antihyperlipemics during preconception period, possibility of diagnosing hyperlipidemia in pregnancy and their treatment during the pregnancy, then lactacy. "

06/01/1990 - "If the short-term safety of these drugs extends to ongoing longterm studies and if cardiovascular morbidity and mortality are improved by their use, these hypolipidemic agents will facilitate the effective treatment of hypercholesterolemia."
06/01/1995 - "Prescribing patterns of antilipemic drugs and prevalence of hypercholesterolemia in the Nova Scotia population more than 65 years old."
02/01/1994 - "[What should be the role of antilipemic agents in the control of hypercholesterolemia in elderly persons?]."
01/01/1989 - "A modest number of hypolipidemic drugs are currently available, and their use as single agents frequently fails to adequately control patients with severe hypercholesterolemia. "
09/01/2001 - "Subjects included 90 ambulatory care patients (60 men, 30 women), age range 21 to 65 years, with hypercholesterolemia and not taking hypolipidemic drugs. "

10/01/1994 - "[Evaluation of various experimental dyslipoproteinemia models in the study of hypolipidemic agents]."
03/01/2014 - "However, management of dyslipidemia in clinical practice may require the use of other hypolipidemic agents in combination with statins. "
10/01/2011 - "The presence of dyslipidemia influenced IMT and may be used as a tool to follow patients on hypolipidemic drugs."
04/03/2010 - "In our opinion, the future treatment of diabetic dyslipidemia will include the combination of statins and other hypolipidemic agents."
04/01/2007 - "If causal treatment of secondary dyslipidemia is possible, hypolipidemic drugs are not indicated. "

06/01/2004 - "Most of the clinical studies that have investigated the plasma levels of PAF-AH activity in cardiovascular disease have involved patients who were under treatment with various drugs, such as antihypertensive or hypolipidemic agents. "
07/01/2015 - "Hypolipidemic drugs are prescribed in the most of cases for the treatment of cardiovascular diseases. "
03/01/2012 - "Thyromimetics represent a new class of hypolipidemic drugs: their imminent application in patients with severe dyslipidemias, combined or not with statins, will improve the lipid profile, potentially accelerate energy expenditure and, as a consequence, vitally lessen the risk of cardiovascular disease."
01/01/2009 - "Children with severe dyslipidemia or additional risk factors such as family history of early cardiovascular disease or other signs of metabolic syndrome may need treatment with hypolipidemic drugs. "
12/01/1994 - "In the secondary prevention trials, nicotinic acid therapy with other hypolipidemic drugs asserted protective effects on the development/progression of cardiovascular disease."

01/01/2014 - "Hypolipidemic drugs are unsuitable for primary prophylaxis of HLP and atherosclerosis that should be based on (a) normalization ofbiological function of trophology and biological reaction ofexotrophy, (b) bringing (by substrate induction) qualitative and quantitative food composition in correspondence with real, rather limited functional capacity of Homo sapiens. "
01/01/2007 - "Statins, hypolipidemic drugs, not only reduce atherogenesis but also stimulate bone formation. "
07/01/1999 - "Individuals with this disorder have a high risk of premature atherosclerosis, and hypolipidemic drugs are useful in their management. "
04/01/1967 - "[Antilipemics and atherosclerosis]."
03/01/2012 - "Addition of Amla to the currently available hypolipidemic therapy would offer significant protection against atherosclerosis and coronary artery disease, with reduction in the dose and adverse effects of the hypolipidemic agents."